Search Result

Results for "

Fusion Inhibitors

" in MedChemExpress (MCE) Product Catalog:

標的別:	Akt (3) Amine N-methyltransferase (1) Amino Acid Derivatives (1) AMPK (2) Anaplastic lymphoma kinase (ALK) (8) Antibiotic (3) Apoptosis (24) Arenavirus (2) Atg8/LC3 (1) ATP Synthase (1) Autophagy (13) Bacterial (6) Bcl-2 Family (1) Bcr-Abl (1) Biochemical Assay Reagents (1) Cadherin (1) Calcium Channel (1) Casein Kinase (2) Caspase (1) CD276/B7-H3 (1) CD3 (1) CD47 (2) CDK (1) CHIKV (5) Complement System (1) CXCR (2) Cytochrome P450 (1) Dengue Virus (1) DNA/RNA Synthesis (1) Dopamine Receptor (1) Drug Derivative (2) Drug Intermediate (1) Drug Isomer (1) EGFR (3) Environmental Pollutants (1) Epigenetic Reader Domain (5) ERK (5) FGFR (3) Filovirus (3) Flavivirus (1) FLT3 (2) FOXO (1) Furin (1) Hepatitis E Virus (HEV) (2) Histone Methyltransferase (3) HIV (18) HSP (2) HSV (2) IGF-1R (1) iGluR (2) Influenza Virus (15) Interleukin Related (4) Isotope-Labeled Compounds (1) JAK (1) JNK (1) Kallikrein (1) Liposome (1) LPL Receptor (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitophagy (1) Molecular Glues (1) mTOR (3) NF-κB (3) Notch (1) NTPDase (1) P-selectin (1) P2X Receptor (1) p62 (1) Parasite (1) PARP (1) PD-1/PD-L1 (1) PDGFR (1) Phosphatase (1) PIKfyve (1) PKA (1) Potassium Channel (1) PROTACs (9) Proton Pump (1) Ras (1) Reference Standards (5) RET (5) RIP kinase (1) ROS Kinase (3) RSV (14) RUNX (1) SARS-CoV (13) STAT (3) TGF-beta/Smad (6) TNF Receptor (10) Transmembrane Glycoprotein (1) Trk Receptor (12) Tyrosinase (1) ULK (1) VEGFR (2) WDR5 (2) Wnt (2) YAP (1) β-catenin (1)
研究分野別:	Cancer (75) Cardiovascular Disease (8) Endocrinology (1) Infection (65) Inflammation/Immunology (28) Metabolic Disease (9) Neurological Disease (8)
クリックケミストリー:	Azide (1) Alkynes (1)

165

阻害剤およびアゴニスト

蛍光色素

ペプチド

阻害性抗体

天然物

同位体標識化合物

クリックケミストリー

Targets Recommended: Serpin

製品番号	製品名	Target	研究分野	構造式

HY-100558

Bafilomycin A1 Maximum Cited Publications 802 Publications Verification BafA1	Proton Pump Autophagy Antibiotic Bacterial Apoptosis	Infection Cancer
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H ⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .

HY-B0795

MHY1485 200+ Cited Publications	mTOR Autophagy	Cancer
MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes .

HY-108847

Etanercept Maximum Cited Publications 15 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-131042

NNMTi 5+ Cited Publications	Amine N-methyltransferase	Metabolic Disease
NNMTi is a potent nicotinamide N-methyltransferase (NNMT) inhibitor (IC₅₀=1.2 μM) and selectively binds to the NNMT substrate-binding site residues . NNMTi promotes myoblast differentiation in vitro and enhances fusion and regenerative capacity of muscle stem cells (muSCs) in aged mice .

HY-112301

Pralsetinib 15+ Cited Publications BLU-667	RET	Cancer
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC₅₀s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively .

HY-13491

GNF-5837 4 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .

HY-P0052

Enfuvirtide 4 Publications Verification T20; DP178	HIV	Infection
Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.

HY-P99720

Luspatercept 5 Publications Verification ACE-536; luspatercept–aamt	TGF-beta/Smad	Metabolic Disease Cancer
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .

HY-152292

Zidesamtinib NVL-520; NUV-520	ROS Kinase	Cancer
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC₅₀s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer .

HY-U00434

3BDO 20+ Cited Publications	mTOR Autophagy Apoptosis	Infection Inflammation/Immunology
3BDO is a IFITM3 modulator and mTOR activator with antiviral and autophagy-inhibiting effects. 3BDO exhibits inhibitory activity against porcine coronaviruses. 3BDO increases the protein abundance of IFITM3, inhibits virus-cell membrane fusion, and blocks viral entry. 3BDO inhibits the entry of transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus into host cells. 3BDO can be used for research on porcine coronavirus infection .

HY-16727

Presatovir 5+ Cited Publications GS-5806	RSV	Infection
Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC₅₀ value of 0.43 nM .

HY-109142

Ziresovir 5 Publications Verification AK0529; RO-0529	RSV	Infection
Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC₅₀=3 nM) and highlights pharmacokinetics in animal species .

HY-14904A

Umifenovir hydrochloride 10+ Cited Publications	Influenza Virus SARS-CoV CHIKV	Infection
Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P99777

Ontorpacept 1 Publications Verification TTI-621	CD47	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-129111

EACC 4 Publications Verification	Autophagy	Infection Neurological Disease
EACC is a reversible autophagy inhibitor, which can block autophagic flux. EACC selectively inhibits the translocation of autophagosome-specific SNARE Stx17 thereby blocking autophagosome-lysosome fusion .

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-14904

Umifenovir 10+ Cited Publications	SARS-CoV Influenza Virus CHIKV	Infection
Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells . Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro . Umifenovir shows anti-inflammatory activity .

HY-150072

DS89002333	PKA	Cancer
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC₅₀ of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .

HY-135072

N,N',N''-Triacetylchitotriose	Bacterial Liposome	Cardiovascular Disease Infection
N,N',N''-Triacetylchitotriose is a competitive Lysozyme inhibitor. N,N',N''-Triacetylchitotriose inhibits the activity of lysozyme. N,N',N''-Triacetylchitotriose reduces the fusion rate between lysozyme-conjugated liposomes and erythrocyte ghosts, and decreases the equilibrium fusion rate .

HY-19810

MI-538 4 Publications Verification	Epigenetic Reader Domain	Cancer
MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.

HY-112180

Rilematovir 5 Publications Verification JNJ-678; JNJ-53718678	RSV	Infection
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.

HY-112698

CA-5f 4 Publications Verification	p62 Atg8/LC3 Autophagy Apoptosis	Cancer
CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .

HY-B1336

Furazolidone 3 Publications Verification	Environmental Pollutants Antibiotic Bacterial Apoptosis Parasite	Infection Cancer
Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research [2].

HY-153386

CPD-1224	Anaplastic lymphoma kinase (ALK)	Cancer
CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .

HY-141429A

AS-99 TFA 2 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 μM, K_d= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-P99845

Dazodalibep MEDI 4920; VIB 4920	TNF Receptor	Inflammation/Immunology
Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome .

HY-11097

TMC353121 5+ Cited Publications	RSV	Infection
TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC₅₀ of 9.9.

HY-128347

M‑89	Epigenetic Reader Domain	Inflammation/Immunology Cancer
M-89 is a highly potent and specific menin inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to study MLL leukemia. M-89 inhibits the cell growth in leukemia cell lines carrying MLL fusion .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-P0052A

Enfuvirtide acetate 4 Publications Verification T20 acetate; DP178 acetate	HIV	Infection
Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.

HY-121219

(-)-Lupinine	Bacterial	Infection
(-)-Lupinine is an alkaloid and membrane fusion inhibitor. (-)-Lupinine does not affect the synthesis of proinflammatory cytokines during the host response to Serratia proteamaculans infection. (-)-Lupinine can enhance the expression of the bacterial surface protein OmpX. (-)-Lupinine can be used for research on bacterial infections .

HY-19587

Ditercalinium chloride NSC335153	DNA/RNA Synthesis	Cancer
Ditercalinium chloride is an anticancer agent. Ditercalinium chloride inhibits human DNA polymerase gamma activity. Ditercalinium chloride can deplete mitochondrial DNA in both mouse and human cells. Ditercalinium chloride is a potential ligand against the COMMD10-AP3S1 fusion protein .

HY-122907

JNJ4796	Influenza Virus	Infection
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .

HY-76648

NBD-556	HIV	Infection
NBD-556, a CD4 mimetic, is a potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels .

HY-12994

VP-14637 MDT-637	RSV	Infection
MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC₅₀ of 1.42 ng/mL.

HY-177120

DMBP	Autophagy	Cancer
DMBP is a VPS41 inhibitor. DMBP induces methuosis and inhibits autophagy in cancer cells. DMBP inhibits the fusion of late endosomes and autophagosomes with lysosomes. DMBP effectively inhibits metastasis in a mouse metastatic melanoma model. DMBP can be used for the study of melanoma .

HY-W048674

Fmoc-Ser(Ac)-OH Fmoc-O-acetyl-L-serine	Amino Acid Derivatives	Infection
Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor .

HY-124871

LASV-IN-1	Arenavirus	Infection
LASV-IN-1 is a Lassa fever virus (LASV) inhibitor. LASV-IN-1 binds with LASV glycoprotein (GP) and promotes virus membrane fusion and infection. LASV-IN-1 can be used for LASV infection research .

HY-159625

WX8 1 Publications Verification Ro 91-4714	PIKfyve	Cancer
WX8 (Ro 91-4714) is an ATP-competitive PIKFYVE inhibitor, with K_d values of 0.9 nM and 340 nM for PIKFYVE and PIP4K2C, respectively. WX8 (Ro 91-4714) inhibits lysosomal fission without effecting homotypic lysosomal fusion. WX8 (Ro 91-4714) is used in the research of autophagy-dependent cancer .

HY-153331

DDO-2213	WDR5	Cancer
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC₅₀ of 29 nM and a K_d value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research .

HY-141429

AS-99 free base 2 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo .

HY-14904AR

Umifenovir hydrochloride (Standard)	Reference Standards Influenza Virus SARS-CoV CHIKV	Infection
Umifenovir (hydrochloride) (Standard) is the analytical standard of Umifenovir (hydrochloride). This product is intended for research and analytical applications. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P991676

Eflumenibep alfa DS-2325A	Kallikrein	Inflammation/Immunology
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .

HY-P991690

Glarivibart	RSV	Infection
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting *Respiratory syncytial virus (RSV) fusion* F protein (RSV-F)**. Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-148202

Influenza antiviral conjugate-1	HIV	Infection
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-150636

Autophagy-IN-1	Autophagy Apoptosis	Cancer
Autophagy-IN-1 is a potent autophagy/mitophagy inhibitor, acts by selectively increasing the autophagic flux while blocking the autophagosome-lysosome fusion in cancer cells. Autophagy-IN-1 can induce apoptosis and cell cycle arrest. Autophagy-IN-1 significantly inhibits tumor growth in an HCT116 xenograft mouse model and with low toxicity. Autophagy-IN-1 can be used for researching colorectal cancer .

製品番号	製品名	Target	研究分野

HY-P0052

Enfuvirtide 4 Publications Verification T20; DP178	HIV	Infection
Enfuvirtide (T20;DP178) is an anti-HIV-1 fusion inhibitor peptide.

HY-P0052A

Enfuvirtide acetate 4 Publications Verification T20 acetate; DP178 acetate	HIV	Infection
Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide.

HY-P4113

TAT-NSF700 Fusion Peptide	ペプチド	Neurological Disease
TAT-NSF700 Fusion Peptide is a potent N-ethyl-maleimide-sensitive factor (NSF) inhibitor. TAT-NSF700 Fusion Peptide can readily permeate the cell membrane and interact with the intracellular organelle directly .

HY-W048674

Fmoc-Ser(Ac)-OH Fmoc-O-acetyl-L-serine	Amino Acid Derivatives	Infection
Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor .

HY-P2200

Siamycin I BMY-29304	HIV Antibiotic	Infection Inflammation/Immunology
Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED₅₀s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-P10517

Sifuvirtide SFT	HIV	Infection
Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .

HY-P4110

TAT-NSF222 Fusion Peptide	iGluR	Metabolic Disease Inflammation/Immunology
TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .

HY-114437

Fusion Inhibitory Peptide Z-D-Phe-Phe-Gly-OH; FIP; Virus Replication Inhibitory Peptide	Influenza Virus	Infection
Fusion Inhibitory Peptide (Z-D-Phe-Phe-Gly-OH, FIP, Virus Replication Inhibitory Peptide) is a potent inhibitor of the virus replication, by inhibiting the membrane fusing activity of a viral glycoprotein .

HY-P5497

C34 peptide	HIV	Others
C34 peptide is a biological active peptide. (This C34 peptide, also known as HR2, belongs to the helical region of gp41 of HIV, C-terminal heptad repeat 2 (HR2) defined as C helix or C peptide. It is known that HIV-1 enters cells by membrane fusion, C34 gp41 peptide is a potent inhibitors of HIV-1 fusion.)

HY-P1753

VIR-165	HIV	Infection
VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains .

HY-P35433

Tifuvirtide T-1249	HIV	Inflammation/Immunology
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .

HY-P10993

CT20p	Bcl-2 Family	Cancer
CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .

HY-P10820

N36Mut(e,g)	HIV	Infection
N36Mut(e,g) is a gp41-targeted HIV fusion peptide inhibitor. N36Mut(e,g) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers .

HY-P10517A

Sifuvirtide acetate SFT acetate	HIV	Infection
Sifuvirtide (SFT) acetate is a potent HIV fusion inhibitor. Sifuvirtide acetate inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide acetate can be used in the research of anti-HIV drugs .

HY-P11037

soVIRIP	HIV	Infection
soVIRIP is a virus inhibitory peptide with an IC₅₀ of 1.2  μM for HIV-1 . soVIRIP binds to the HIV-1 GP41 fusion peptide and inhibits viral fusion and entry into host cells. soVIRIP has broad-spectrum anti-HIV-1 activities with nontoxicity in zebrafish models. soVIRIP can used for viral infections research .

HY-P10308

[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92)	HIV	Infection
[(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) is a selective inhibitor of HIV-1. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) inhibits viral infection and cell fusion by blocking the interaction between HIV-1 and CD4 molecules. [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) can completely inhibit fusion formation at a concentration of 25 μM .

HY-P10437

VIRIP human α1-AT(353-372)	HIV	Infection
VIRIP (human α1-AT(353-372)) is a HIV-1 inhibitor. VIRIP blocks the entry of HIV-1 by interacting with gp41 fusion peptide. VIRIP can be used for virus research .

HY-P10801

mC46 peptide C46 peptide	HIV	Infection
mC46 (C46) peptide is a membrane-associated fusion peptide inhibitor. mC46 peptide potently inhibits HIV-1 replication and entry. mC46 also inhibits CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, SIV, and SHIV .

HY-106428

Icrocaptide ITF1697	P-selectin	Cardiovascular Disease Inflammation/Immunology
Icrocaptide (ITF1697) is a stable Lys-Pro-containing peptide that inhibits the intracellular Ca ²⁺-dependent fusion of Weibel-Palade bodies with the plasma membrane. Icrocaptide exerts its activity at the early stages of endothelial activation and inhibits P-selectin and von Willebrand factor secretion. Icrocaptide can be used for the study of a variety of microvascular disorders .

HY-P10804

PIH	SARS-CoV	Infection
PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC₅₀ of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold .

HY-P5395

TAT-GluR23A Fusion Peptide	HIV	Others
TAT-GluR23A Fusion Peptide is a biological active peptide. (This is the GluR23A sequence, a control inactive peptide used as a mutant counterpart to glutamate receptor endocytosis inhibitor (GluR23Y), connected to an 11 amino acid cell permeable HIV Trans-Activator of Transcription (TAT) protein transduction domain (PTD). GluR23A is derived from GluR23Y amino acids 869 to 877, with Ala substituted for Tyr, and thus lacking essential phosphorylation sites.Control peptide of HY-P2259)

HY-P3492

SARS-CoV-2-IN-34	SARS-CoV	Infection
SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .

HY-P1058

Pep2m	iGluR	Neurological Disease
Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression ^{[1] [2] [3] [4] [5]}.

HY-P11766

GALA-chol GALA-cholesterol	Biochemical Assay Reagents	Cancer
GALA-chol is a cholesterol-conjugated pH-responsive fusion peptide that can serve as a delivery adjuvant. GALA-chol enhances the endocytosis of siRNA RET/PTC1-SQ nanoparticles, inhibits cell viability, and undergoes pH-responsive charge conversion in the acidic lysosomal environment, thereby promoting lysosomal escape of small extracellular vesicle (sEV) cargo. GALA-chol anchors to the sEV membrane and maintains the structural integrity and intrinsic homing activity of sEVs. GALA-chol can be used in studies related to adjuvant delivery .

製品番号	製品名	Target	研究分野	Image

HY-108847

Etanercept Maximum Cited Publications 15 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99568

Telitacicept RC18	TNF Receptor	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease . The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.

HY-P99720

Luspatercept 5 Publications Verification ACE-536; luspatercept–aamt	TGF-beta/Smad	Metabolic Disease Cancer
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .

HY-P990706

Povetacicept ALPN-303	TNF Receptor	Inflammation/Immunology
Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The K_d value of Povetacicept for human BAFF is 59.3 pM, while its K_d value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis .

HY-P99268

Seribantumab SAR 256212; MM 121	EGFR Apoptosis	Cancer
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .

HY-P991049

Atrosimab ATM-001	TNF Receptor	Metabolic Disease Inflammation/Immunology
Atrosimab is an Fv-Fc1K fusion protein with an EC₅₀ value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .

HY-P99777

Ontorpacept 1 Publications Verification TTI-621	CD47	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99950

Evorpacept ALX148	CD47	Cancer
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-P99845

Dazodalibep MEDI 4920; VIB 4920	TNF Receptor	Inflammation/Immunology
Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome .

HY-P99459

Baminercept 2 Publications Verification BG 9924; TT-47	TNF Receptor CXCR	Inflammation/Immunology
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-P99928

Efprezimod alfa MK 7110; CD24 Fc	Transmembrane Glycoprotein	Cancer
Efprezimod alfa (MK 7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome .

HY-P991059

VIS-410	Influenza Virus	Infection
VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC₅₀ = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection .

HY-P99830

Conbercept KH902	VEGFR TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC₅₀ = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (K_d = 0.5 pM), VEGF-B (K_d = 8 pM), VEGF-C, and PlGF (K_d = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a PD-L1 inhibitor and a VEGF inhibitor .

HY-P991676

Eflumenibep alfa DS-2325A	Kallikrein	Inflammation/Immunology
Eflumenibep alfa is a Kallikrein 5 inhibitor with anti-inflammatory activity. Eflumenibep alfa is a fusion protein that combines human SPINK2 with the human IgG1 Fc fragment at the C-terminus .

HY-P991690

Glarivibart	RSV	Infection
Glarivibart is a humanized IgG1κ monoclonal antibody inhibitor targeting *Respiratory syncytial virus (RSV) fusion* F protein (RSV-F)**. Glarivibart has significant antiviral activity. Glarivibart can be used for RSV infections research .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P99782

Opinercept	TNF Receptor	Inflammation/Immunology
Opinercept is a recombinant fusion protein comprising an TNFRSF1B fused to a human IgG1 Fc . Opinercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor. Opinercept can be used for the research of rheumatoid arthritis (RA) .

HY-P991311

GSK3178022	LPL Receptor Wnt	Cancer
GSK3178022 is a human IgG1 monoclonal antibody (mAb) targeting LRP6. GSK3178022 inhibits the expression of WNT target genes SP5 and AXIN2. GSK3178022 has antitumor activity in the RSPO fusion model of colorectal cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P990708

Bizaxofusp MDNA55; NBI-3001; PRX-321	Interleukin Related Apoptosis	Inflammation/Immunology Cancer
Bizaxofusp (MDNA55) is a fusion protein formed by the linkage of IL-4 and a truncated Pseudomonas exotoxin. Bizaxofusp can bind to IL-4 receptors on the surface of tumor cells and be internalized, and its exotoxin moiety can inhibit protein synthesis and induce tumor cell apoptosis. Bizaxofusp can be used in the study of cancer .

HY-P990963

Albipagrastim alfa	阻害性抗体	Inflammation/Immunology Cancer
Albipagrastim alfa is a long-acting granulocyte colony-stimulating factor (G-CSF), which is formed by the fusion of highly active recombinant G-CSF and human serum albumin (HSA). Albipagrastim alfa can significantly inhibit the clearance pathway mediated by the G-CSF receptor. Albipagrastim alfa can be used in tumor-related research .

HY-P990955

Ebribafusp alfa ADX-097	CD3 Complement System	Inflammation/Immunology
Ebribafusp alfa (ADX-097) is a bifunctional fusion protein composed of a humanized anti-C3d monoclonal antibody linked to the first five common repeat (fH1-5) domains of two complement factors H. Ebribafusp alfa is a tissue-targeted complement inhibitor designed to inhibit complement activity at the lesion site while minimizing systemic complement blockade. Ebribafusp alfa can be used for research on kidney diseases, lupus nephritis, and complement component 3 glomerulonephropathy . The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-P992175

ADI-14448	RSV	Infection
ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a K_d of 3.8 × 10 ^-10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection .

HY-P991766

Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57)	Flavivirus	Infection
Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) reacts with the E2 protein of the Venezuelan equine encephalitis virus (VEEV). Anti-Venezuelan equine encephalitis virus E2 protein Antibody (VEEV-57) inhibits VEEV attachment to Vero cells, viral egress, viral fusion, and LDLRAD3-D1-Fc binding. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981) .

製品番号	製品名	Category	Target	構造式

HY-100558

Bafilomycin A1 Maximum Cited Publications 802 Publications Verification BafA1	Infection Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Disease Research Anticancer Disease Research Fields Source Classification	Proton Pump Autophagy Antibiotic Bacterial Apoptosis
Bafilomycin A1 (BafA1) is a specific and reversible inhibitor of vacuolar H ⁺-ATPase (V-ATPase) with IC₅₀ values of 4-400 nmol/mg. Bafilomycin A1, a macrolide antibiotic, is also used as an autophagy inhibitor at the late stage. Bafilomycin A1 blocks autophagosome-lysosome fusion and inhibits acidification and protein degradation in lysosomes of cultured cells. Bafilomycin A1 induces apoptosis .

HY-N0559

Kirenol 1 Publications Verification	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .

HY-N0485

Liensinine Diperchlorate 15+ Cited Publications	Cardiovascular Disease Alkaloids Piperidine Alkaloids Classification of Application Fields Phenols Polyphenols Nelumbo nucifera Gaertn. Plants Disease Research Fields Nymphaeaceae Source Classification	Autophagy Mitophagy
Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlorate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .

HY-135072

N,N',N''-Triacetylchitotriose	Infection Structural Classification Polysaccharides Microorganisms Animals Classification of Application Fields Disease Research Fields Saccharides Source Classification	Bacterial Liposome
N,N',N''-Triacetylchitotriose is a competitive Lysozyme inhibitor. N,N',N''-Triacetylchitotriose inhibits the activity of lysozyme. N,N',N''-Triacetylchitotriose reduces the fusion rate between lysozyme-conjugated liposomes and erythrocyte ghosts, and decreases the equilibrium fusion rate .

HY-N0899

Wilforine	Cardiovascular Disease Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Celastraceae Tripterygium wilfordii Hook. f. Plants Disease Research Fields Source Classification	JAK STAT Wnt β-catenin
Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .

HY-N4299

Caesappanin C	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Other Phenylpropanoids Phenols Polyphenols Metabolic Disease Phenylpropanoids Plants Disease Research Fields Source Classification	HSV HSP
Caesappanin C, a biphenyl dimer from the ethanolic extract of the heartwood of Indonesian Caesalpinia sappan L., shows strong proliferation stimulating activity against the primary osteoblastic cells in vitro. Caesappanin C has the potential to stimulate bone formation and regeneration . Caesappanin C can effectively deactivate HSV particles and bind HSV surface glycoprotein B (gB) to inhibit membrane fusion .

HY-N3855

Erythrabyssin II	Leguminosae Phenols Polyphenols Plants Erythrina crista-galli Linn. Source Classification	Autophagy Apoptosis
Erythrabyssin II (EL-19) is a potent late-stage autophagy inhibitor that blocks the fusion of autophagosome and lysosome. Erythrabyssin II leads to the accumulation of autophagic substrates and does not impair lysosomal pH or lysosomal enzyme activity. Erythrabyssin II suppresses ovarian cancer organoid activity and induces apoptosis. Erythrabyssin II can be used for the study of ovarian cancer .

HY-N10177

Peniterphenyl A	Infection Microorganisms Classification of Application Fields Phenols Polyphenols Disease Research Fields Source Classification	HSV
Peniterphenyl A is a natural product obtained from a deep-sea-derived Penicillium sp. Peniterphenyl A inhibits HSV-1/2 virus entry into cells and may block HSV-1/2 infection through direct interaction with virus envelope glycoprotein D to interfere with virus adsorption and membrane fusion. Peniterphenyl A is a promising lead compound against HSV-1/2 .

HY-173150

Hapalindole Q	Structural Classification Alkaloids Microorganisms Other Alkaloids Source Classification	YAP
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a K_d of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .

HY-N0559R

Kirenol (Standard)	Structural Classification Terpenoids Bituminaria morisiana (Pignatti & Metlesics) Greuter Diterpenoids Plants Compositae Source Classification	Reference Standards Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad
Kirenol (Standard) is the analytical standard of Kirenol (HY-N0559). This product is intended for research and analytical applications. Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a K_d value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis.

HY-N12768

Rhodojaponin VI	Structural Classification Terpenoids Diterpenoids Pieris japonica (Thunb.) D. Don ex G. Don Ericaceae Plants Source Classification	MDM-2/p53 Notch Calcium Channel
Rhodojaponin VI is an orally active diterpenoid compound found in hododendron molle G. Don (Ericaceae) (RM). Rhodojaponin VI binds rat N-Ethylmaleimide-sensitive fusion (NSF) with a Kd of 1.03 μM. Rhodojaponin VI blocks the MDM2-Notch1 signalling pathway by reducing MDM2 and Notch1 expression. Rhodojaponin VI indirectly reduces Cav_2.2 current intensity by inhibiting NSF-mediated Cav2.2 trafficking. Rhodojaponin VI alleviates glomerulonephritis progression and podocyte injury in passive heymann nephritis rats. Rhodojaponin VI also has antinociceptive effects. Rhodojaponin VI can be used for the researches of heymann nephritis and pain .

製品番号	製品名	構造式

HY-14904AS

Umifenovir-d6 hydrochloride

Umifenovir-d₆ (hydrochloride) is the deuterium labeled Umifenovir hydrochloride. Umifenovir hydrochloride is a potent, orally active broad-spectrum antiviral with activity against a number of enveloped and non-enveloped viruses. Umifenovir hydrochloride is used as an anti-influenza virus agent. Umifenovir hydrochloride could effectively inhibit the fusion of virus with host cells . Umifenovir hydrochloride is an efficient inhibitor of SARS-CoV-2 in vitro. Anti-inflammatory activity .

製品番号	製品名		Classification

HY-159147

SIAIS039		Azide
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .

HY-148202

Influenza antiviral conjugate-1		Alkynes
Influenza antiviral conjugate-1 (INT-2) is a HIV inhibitor, shows potent cell fusion inhibition . Influenza antiviral conjugate-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: